Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative ...
KELOWNA, BC / / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a ...
− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, ...
Phesi’s report of the world’s most-studied diseases has become a holiday tradition, and this year’s list features few surprises. | Phesi’s report of the world’s most-studied diseases has become a ...
The Center for Information and Study on Clinical Research Participation (CISCRP) has launched an interactive data dashboard, giving clinical research stakeholders customized access to data from the ...
Concerns about the safety and efficacy of mRNA COVID-19 shots have increased after a January 3 report that drug maker Moderna failed to inform the U.S. government of the death of a child during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback